
NRC Health (NRC) Stock Forecast & Price Target
NRC Health (NRC) Analyst Ratings
Bulls say
NRC Health is attractive because its 3Q26 results showed both revenue and profitability ahead of expectations, with $38.4M of revenue and $10.9M of EBITDA supported by recurring subscription demand and a successful large customer go-live. The company’s visibility is reinforced by a $154M TRCV base, multi-year renewals, and a second phase of the large customer’s rollout scheduled for 3Q27, while management expects sequential margin improvement in 4Q and analysts see revenue growth resuming in 2026 and strengthening in 2027. Its differentiated healthcare-specific platform, Best in KLAS recognition, expanding cross-sell opportunity, and improving execution under new leadership support the view that NRC can rebuild top-line growth and move back toward higher historical profitability.
Bears say
NRC Health is facing a weak fundamental setup because industry consolidation may lengthen sales cycles, while attempts to reaccelerate Insights and TGI growth may fall short and leave expense assumptions too optimistic. Profitability is also pressured by elevated investment in product and personnel, with SG&A approximating 40% of revenue in 2025, or 31% excluding one-time and non-cash items, up from 30% in 2024, suggesting limited near-term margin expansion. The company’s dependence on a concentrated customer base, potential leverage increases from dividends and buybacks, and thin liquidity with a 12M-share float and under 125K average daily volume further weaken the risk-reward profile.
This aggregate rating is based on analysts' research of NRC Health and is not a guaranteed prediction by Public.com or investment advice.
NRC Health (NRC) Analyst Forecast & Price Prediction
Start investing in NRC Health (NRC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About NRC Health (NRC) Forecast
NRC Health (NRC) Analyst Forecast & Price Prediction
Start investing in NRC Health (NRC)
Order type
Buy in
Order amount
Est. shares
0 shares